Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 442

1.

Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality.

Harboe ZB, Dalby T, Weinberger DM, Benfield T, Mølbak K, Slotved HC, Suppli CH, Konradsen HB, Valentiner-Branth P.

Clin Infect Dis. 2014 Oct 15;59(8):1066-73. doi: 10.1093/cid/ciu524. Erratum in: Clin Infect Dis. 2014 Dec 15;59(12):1812.

PMID:
25034421
2.

Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway.

Steens A, Bergsaker MA, Aaberge IS, Rønning K, Vestrheim DF.

Vaccine. 2013 Dec 16;31(52):6232-8. doi: 10.1016/j.vaccine.2013.10.032.

PMID:
24176490
3.

Impact of pneumococcal vaccination in Denmark during the first 3 years after PCV introduction in the childhood immunization programme.

Ingels H, Rasmussen J, Andersen PH, Harboe ZB, Glismann S, Konradsen H, Hoffmann S, Valentiner-Branth P, Lambertsen L; Danish Pneumococcal Surveillance Collaboration Group 2009-2010..

Vaccine. 2012 Jun 6;30(26):3944-50. doi: 10.1016/j.vaccine.2012.03.060.

PMID:
22504662
4.

Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance.

Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Lexau C, Bennett NM, Petit S, Zansky SM, Harrison LH, Reingold A, Miller L, Scherzinger K, Thomas A, Farley MM, Zell ER, Taylor TH Jr, Pondo T, Rodgers L, McGee L, Beall B, Jorgensen JH, Whitney CG.

Lancet Infect Dis. 2015 Mar;15(3):301-9. doi: 10.1016/S1473-3099(14)71081-3.

5.

Serotype distribution of invasive Streptococcus pneumoniae in Canada after the introduction of the 13-valent pneumococcal conjugate vaccine, 2010-2012.

Demczuk WH, Martin I, Griffith A, Lefebvre B, McGeer A, Lovgren M, Tyrrell GJ, Desai S, Sherrard L, Adam H, Gilmour M, Zhanel GG; Toronto Bacterial Diseases Network.; Canadian Public Health Laboratory Network..

Can J Microbiol. 2013 Dec;59(12):778-88. doi: 10.1139/cjm-2013-0614.

PMID:
24313450
6.
7.
8.

Pediatric invasive pneumococcal disease caused by vaccine serotypes following the introduction of conjugate vaccination in Denmark.

Harboe ZB, Valentiner-Branth P, Ingels H, Rasmussen JN, Andersen PH, Bjerre CC, Goldblatt D, Ashton L, Haston M, Konradsen HB, Lambertsen L; Danish Pneumococcal Surveillance Collaborating Group..

PLoS One. 2013;8(1):e51460. doi: 10.1371/journal.pone.0051460.

9.

Epidemiologic characteristics, serotypes, and antimicrobial susceptibilities of invasive Streptococcus pneumoniae isolates in a nationwide surveillance study in Lebanon.

Hanna-Wakim R, Chehab H, Mahfouz I, Nassar F, Baroud M, Shehab M, Pimentel G, Wasfy M, House B, Araj G, Matar G, Dbaibo G; Lebanese Inter-Hospital Pneumococcal Surveillance Program..

Vaccine. 2012 Dec 31;30 Suppl 6:G11-7. doi: 10.1016/j.vaccine.2012.07.020.

PMID:
23228352
10.

Forecasting invasive pneumococcal disease trends after the introduction of 13-valent pneumococcal conjugate vaccine in the United States, 2010-2020.

Link-Gelles R, Taylor T, Moore MR; Active Bacterial Core Surveillance Team..

Vaccine. 2013 May 24;31(22):2572-7. doi: 10.1016/j.vaccine.2013.03.049.

PMID:
23583813
11.

Expansion of serotype coverage in the universal pediatric vaccination calendar: short-term effects on age- and serotype-dependent incidence of invasive pneumococcal clinical presentations in Madrid, Spain.

Picazo J, Ruiz-Contreras J, Casado-Flores J, Negreira S, García-de-Miguel MJ, Hernández-Sampelayo T, Otheo E, Méndez C; HERACLES Study Group..

Clin Vaccine Immunol. 2013 Oct;20(10):1524-30. doi: 10.1128/CVI.00239-13.

12.

Cost-effectiveness of a 10- versus 13-valent pneumococcal conjugate vaccine in Denmark and Sweden.

Klok RM, Lindkvist RM, Ekelund M, Farkouh RA, Strutton DR.

Clin Ther. 2013 Feb;35(2):119-34. doi: 10.1016/j.clinthera.2012.12.006.

PMID:
23312274
13.

Nearly complete elimination of the 7-valent pneumococcal conjugate vaccine serotypes in Tennessee.

Halasa NB, Grijalva CG, Arbogast PG, Talbot TR, Craig AS, Griffin MR, Schaffner W.

Pediatr Infect Dis J. 2013 Jun;32(6):604-9. doi: 10.1097/INF.0b013e318287fe0d.

PMID:
23348816
14.
15.

Four years of universal pneumococcal conjugate infant vaccination in Germany: impact on incidence of invasive pneumococcal disease and serotype distribution in children.

van der Linden M, Weiß S, Falkenhorst G, Siedler A, Imöhl M, von Kries R.

Vaccine. 2012 Aug 31;30(40):5880-5. doi: 10.1016/j.vaccine.2012.06.068.

PMID:
22771186
16.

Pneumococcal carriage in children and adults two years after introduction of the thirteen valent pneumococcal conjugate vaccine in England.

van Hoek AJ, Sheppard CL, Andrews NJ, Waight PA, Slack MP, Harrison TG, Ladhani SN, Miller E.

Vaccine. 2014 Jul 23;32(34):4349-55. doi: 10.1016/j.vaccine.2014.03.017.

PMID:
24657717
17.

Reduction of invasive pneumococcal disease 3 years after the introduction of the 13-valent conjugate vaccine in the Oxfordshire region of England.

Moore CE, Paul J, Foster D, Mahar SA, Griffiths D, Knox K, Peto TE, Walker AS, Crook DW; Oxford Invasive Pneumococcal Surveillance Group..

J Infect Dis. 2014 Oct 1;210(7):1001-11. doi: 10.1093/infdis/jiu213.

PMID:
24719477
18.

Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001-2012.

Lepoutre A, Varon E, Georges S, Dorléans F, Janoir C, Gutmann L, Lévy-Bruhl D; Microbiologists of Epibac.; ORP Networks..

Vaccine. 2015 Jan 3;33(2):359-66. doi: 10.1016/j.vaccine.2014.11.011.

PMID:
25448105
19.

Impact of introduction of conjugate vaccines in the vaccination schedule on the incidence of pediatric invasive pneumococcal disease requiring hospitalization in Madrid 2007 to 2011.

Picazo J, Ruiz-Contreras J, Casado-Flores J, Giangaspro E, García-de-Miguel MJ, Hernández-Sampelayo T, Otheo E, Méndez C; Heracles Study Group..

Pediatr Infect Dis J. 2013 Jun;32(6):656-61. doi: 10.1097/INF.0b013e31827e8594.

PMID:
23249906
20.

Rapid reduction in invasive pneumococcal disease after introduction of PCV7 into the National Immunization Plan in Israel.

Ben-Shimol S, Greenberg D, Givon-Lavi N, Elias N, Glikman D, Rubinstein U, Dagan R; Israeli Bacteremia and Meningitis Active Surveillance Group..

Vaccine. 2012 Oct 12;30(46):6600-7. doi: 10.1016/j.vaccine.2012.08.012.

PMID:
22939907

Supplemental Content

Support Center